As part of our deep commitment to improving the quality of life and healthcare of people with diabetes and other metabolic diseases, we support our clients to explore the full range of diabetes treatment and prevention innovations taking into account the high diversity of disease trigger and pathogenetic traits (Figure 1).
One major challenge to be addressed by innovations in diabetes is the demographic transition towards an ageing society, especially with the related predisposition to frailty, disability and premature death.
Implementing smart products and services for diabetes prevention and care to address ageing has great potential. At Profil, we concur with WHO policy and are committed to an integrated approach to lifestyle and disease when aligning target groups to health goals, considering risk–benefit balances of innovations, and exploring health- and process-related performance indicators (Figure 2).
Combining molecular profiling with the consideration of an individual’s traits, goals and preferences may optimize the precision fit of measures for diabetes prevention and treatment. The identification of patient-specific diabetes signatures and polypharmacy profiles promotes the implementation of more personalized treatments. Comorbidity-adjusted diabetes care acknowledges the high diversity in functional reserves and cognitive performances—factors that critically determine self-management capabilities, treatment benefit and the likelihood of hospitalization.
Profil has a large methodological portfolio for anthropometric, metabolic and cardiovascular assessments, and our clinical trials include careful monitoring of treatment effect modifiers, such as dietary and physical activity habits. Our database of potential trial subjects contains lifestyle and medical data and we are in regular contact with over 30,000 people representing the entire diversity of groups targeted by innovations in diabetes.
We are active with the Center for Biomarker Research in Medicine (CBmed), which puts us in the position to connect our integrated service portfolio with advanced “omics” analytical platforms and provides access to the largest European biobanks and a digital pathology platform.
In order to be even more proactive in meeting the requirements of its clients, Profil Germany decided to become a core partner of EIT Health—one of the largest publicly funded initiatives for health worldwide. This opens up new avenues for extending our service portfolio to accommodate paradigm shifts in the evaluation, licensing and reimbursement of drugs and devices. EIT Health provides access to living labs and test beds that complement our activities in patient-initiated research. In concert with EIT Health partners, we are able to design a framework for the development and marketing of people-centered innovations in diabetes—innovations that will also help us to further expand our service portfolio for the benefit of our clients.